DESTINY-Breast04: Trastuzumab Deruxtecan in HR+/HER2-Low Metastatic Breast Cancer
Breast cancer specialists review key efficacy and safety data from the DESTINY-Breast04 trial investigating trastuzumab deruxtecan in patients with HR+/HER2-low metastatic breast cancer.
EP: 1.Treatment Sequencing and Unmet Needs in HR+/HER2-Low Metastatic Breast Cancer
EP: 2.DESTINY-Breast04: Trastuzumab Deruxtecan in HR+/HER2-Low Metastatic Breast Cancer
EP: 3.Best Candidates for HER2-Directed ADCs in HR+/HER2-Low Metastatic Breast Cancer
EP: 4.Insights on T-DXd and Emerging Research on ADCs in HR+/HER2-Low Breast Cancer
Video content above is prompted by the following questions:
- Please review key efficacy and safety data from the DESTINY-Breast04 trial, evaluating trastuzumab deruxtecan (T-DXd) in patients with HR+, HER2-low metastatic breast cancer.
- What are the clinical implications of these data in your practice?
- What notable adverse events (AEs) have you observed in your practice?
- What mitigation strategies have been implanted in your practice to combat AEs of special interest?
Beyond HER2: The Rise of Antibody-Drug Conjugates in Breast Cancer Treatment
June 26th 2024Tanya Gupta, MD, highlighted the approved indications for antibody-drug conjugates in breast cancer, the efficacy data supporting their approvals, and ongoing studies to advance the space further.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Testing and Treatment Exposure Affect Options in Advanced Breast Cancer
June 18th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed biomarker testing and treatment exposure for a patient with metastatic breast cancer in the second article of a 2-part series.
Read More
